Mohammed Z. Zamer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mohammed Z. Zamer has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Austin G. Duffy
Department of Medical Oncology, The Mater Hospital, D07 R2WY Dublin, Ireland
1 shared publication - Caitriona Cahir
Royal College of Surgeons in Ireland, Dublin, Ireland
1 shared publication - Catherine Margaret Kelly
Catherine M. Kelly, MD, Trinity St James's Cancer Centre at St James's Hospital, Dublin, Ireland
1 shared publication - Darren Cowzer
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
1 shared publication Emily Harrold
1 shared publicationJanice M. Walshe
1 shared publication
Latest Publications
- Open Access
- 22 September 2026
- Published by Elsevier in The Breast
- Vol. 90
Prospective assessment of incomplete ovarian suppression in breast cancer using LC-MS/MS and immunoassays for estradiol
- 22 September 2026
- Published by Elsevier in The Breast
- Vol. 90
Open AccessProspective assessment of incomplete ovarian suppression in breast cancer using LC-MS/MS and immunoassays for estradiol
- Open Access
- 8 November 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (11) , 1870
Targeting KRAS in Pancreatic Cancer
Pancreatic cancer is mainly driven by mutations in the KRAS oncogene. While this cancer has shown remarkable therapy resistance, new approaches to inhibit mutated KRAS, KRAS activators and effectors show promise in breaking this therapeutic deadlock. Here, we review these innovations in therapies that target RAS signaling in pancreatic cancer from a clinical point of view. A number of promising approaches are currently in clinical trials or in clinical development. We focus on small-molecule drugs but also discuss immunotherapies and tumor vaccines.
- 8 November 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (11) , 1870
Open AccessTargeting KRAS in Pancreatic Cancer
Pancreatic cancer is mainly driven by mutations in the KRAS oncogene. While this cancer has shown remarkable therapy resistance, new approaches to inhibit mutated KRAS, KRAS activators and effectors show promise in breaking this therapeutic deadlock. Here, we review these innovations in therapies that target RAS signaling in pancreatic cancer from a clinical point of view. A number of promising approaches are currently in clinical trials or in clinical development. We focus on small-molecule drugs but also discuss immunotherapies and tumor vaccines.